Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QK61 | ISIN: DK0061411964 | Ticker-Symbol: 8GN
Frankfurt
28.03.24
15:29 Uhr
0,732 Euro
-0,008
-1,08 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CESSATECH A/S Chart 1 Jahr
5-Tage-Chart
CESSATECH A/S 5-Tage-Chart

Aktuelle News zur CESSATECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMinutes from the Annual General Meeting in Cessatech A/S1
11.03.CESSATECH: Annual General Meeting - 27 March 20242
29.02.Cessatech A/S publishes Annual Report for the fiscal year 20232
30.01.CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO22
23.01.Last Day Of Trading In Warrants Of Series To2 In Cessatech Is Tomorrow, January 24, 20241
22.01.CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO22
19.01.Spotlight Stock Market: Market Notice 13/24- Last day of trading in Cessatech A/S's subscription option CESSA TO 21
12.01.CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO21
11.01.CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD1
04.01.CESSATECH: Q&A session related topline data Study 02052
16.11.23CESSATECH: Third Quarter Report Q3-20234
25.10.23Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children2
21.09.23Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001298Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of CT001 relative to placebo and two comparative active arms Primary aim is to show that CT001...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1